


PRIORITY DOCUMENT
RECEIVED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)



REC'D 19 APR 2004

WIPO

PCT

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

April 16, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/448,307

FILING DATE: February 14, 2003

RELATED PCT APPLICATION NUMBER: PCT/US04/02015

CD DISK IS THE APPLICATION FOR THE ABOVE REFERENCED
INFORMATION

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



P. SWAIN
Certifying Officer

Due to the format in which this priority document
and accompanying certification was transmitted, the
International Bureau has been unable to upload these
documents in full into its information systems. Only
a copy of the certification page and the first four
pages of the specification are enclosed herewith. The
International Bureau will provide a complete copy of
this document upon request.

P-16180

-1-

5 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS

FIELD OF THE INVENTION

The present invention relates to compounds of peroxisome proliferator activated receptor (PPAR) agonists, more specifically sulfonamide derivatives of PPAR agonists, which are useful for the treatment and/or prevention of disorders modulated by a PPAR agonist.

BACKGROUND OF THE INVENTION

The peroxisome proliferator activated receptors (PPARs) are members of the nuclear receptor gene family that are activated by fatty acids and fatty acid metabolites. The PPARs belong to the subset of nuclear receptors that function as heterodimers with the 9-*cis* retinoic acid receptor (RXR). Three subtypes, designated PPAR α , PPAR γ and PPAR δ , are found in species ranging from *Xenopus* to humans.

PPAR α is the main subtype in the liver and has facilitated analysis of the mechanism by which peroxisome proliferators exert their pleiotropic effects. PPAR α is activated by a number of medium and long-chain fatty acids, and it is involved in stimulating β -oxidation of fatty acids. PPAR α is also involved with the activity of fibrates and fatty acids in rodents and humans. Fibric acid derivatives such as clofibrate, fenofibrate, bezafibrate, ciprofibrate, beclofibrate and etofibrate, as well as gemfibrozil, produce a substantial reduction in plasma triglycerides along with moderate reduction in low-density lipoprotein (LDL) cholesterol, and they are used particularly for the treatment of hypertriglyceridemia.

30	"Express Mail" mailing label number <u>EL232269647US</u>				
	Date of Deposit <u>2-14-03</u>				
35	I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Arlington, VA 22202.				
40	<table><tr><td><u>BUSHEL Thomas</u></td><td><u>Buschel Thomas</u></td></tr><tr><td>Printed Name</td><td>Signature</td></tr></table>	<u>BUSHEL Thomas</u>	<u>Buschel Thomas</u>	Printed Name	Signature
<u>BUSHEL Thomas</u>	<u>Buschel Thomas</u>				
Printed Name	Signature				

5 PPAR γ is the main subtype in adipose tissue and involved in activating the
program of adipocyte differentiation. PPAR γ is not involved in stimulating peroxisome
proliferation in the liver. There are two isomers of PPAR γ : PPAR γ 1 and PPAR γ 2, which
differ only in that PPAR γ 2 contains an additional 28 amino acids present at the amino
terminus. The DNA sequences for the PPAR γ receptors are described in Elbrecht, et al.,
10 BBRC 224;431-437 (1996). Although peroxisome proliferators, including the fibrates
and fatty acids, activate the transcriptional activity of PPAR's, only prostaglandin J₂
derivatives have been identified as natural ligands for PPAR γ , which also binds the anti-
diabetic agents thiazolidinediones with high affinity. The physiological functions of
PPAR α and PPAR γ in lipid and carbohydrate metabolism were uncovered once it was
15 recognized that they were the receptors for the fibrate and glitazone drugs, respectively.

PPAR α and PPAR γ receptors have been implicated in diabetes mellitus,
cardiovascular disease, obesity, and gastrointestinal disease, such as inflammatory bowel
disease and other inflammation related illnesses. Such inflammation related illnesses
include, but are not limited to Alzheimer's disease, Crohn's disease, rheumatoid arthritis,
20 psoriasis, and ischemia reprofusion injury.
By contrast, PPAR δ (also referred to as PPAR β and NUC1) is not reported to be receptor
for any known class of drug molecules, and its role in mammalian physiology has
remained undefined. The human nuclear receptor gene PPAR δ (hPPAR δ) has been
cloned from a human osteosarcoma cell cDNA library and is fully described in A.
25 Schmidt et al., *Molecular Endocrinology*, 6:1634-1641 (1992).

Diabetes is a disease in which a mammal's ability to regulate glucose
levels in the blood is impaired because the mammal has a reduced ability to convert
glucose to glycogen for storage in muscle and liver cells. In Type I diabetes, this reduced
ability to store glucose is caused by reduced insulin production. "Type II Diabetes" or
30 "non-insulin dependent diabetes mellitus" (NIDDM) is the form of diabetes, which is due
to a profound resistance to insulin stimulating or regulatory effect on glucose and lipid
metabolism in the main insulin-sensitive tissues, muscle, liver and adipose tissue. This
resistance to insulin responsiveness results in insufficient insulin activation of glucose
uptake, oxidation and storage in muscle and inadequate insulin repression of lipolysis in
35 adipose tissue and of glucose production and secretion in liver. When these cells become

5 desensitized to insulin, the body tries to compensate by producing abnormally high levels
of insulin and hyperinsulemia results. Hyperinsulemia is associated with hypertension
and elevated body weight. Since insulin is involved in promoting the cellular uptake of
glucose, amino acids and triglycerides from the blood by insulin sensitive cells, insulin
insensitivity can result in elevated levels of triglycerides and LDL (known as the "bad"
10 cholesterol) which are risk factors in cardiovascular diseases. The constellation of
symptoms which includes hyperinsulemia combined with hypertension, elevated body
weight, elevated triglycerides and elevated LDL is known as Syndrome X.

Hyperlipidemia is a condition which is characterized by an abnormal
increase in serum lipids, such as cholesterol, triglycerides and phospholipids. These lipids
15 do not circulate freely in solution in plasma, but are bound to proteins and transported as
macromolecular complexes called lipoproteins. One form of hyperlipidemia is
hypercholesterolemia, characterized by the existence of elevated LDL cholesterol levels.
The initial treatment for hypercholesterolemia is often a diet low in fat and cholesterol
coupled with appropriate physical exercise. Drug intervention is initiated if LDL-
20 lowering goals are not met by diet and exercise alone. It is desirable to lower elevated
levels of LDL cholesterol and increase levels of HDL cholesterol. Generally, it has been
found that increased levels of HDL are associated with lower risk for coronary heart
disease (CHD). See Gordon, et al., *Am. J. Med.*, 62, 707-714 (1977); Stampfer, et al., *N.*
England J. Med., 325, 373- 381 (1991); and Kannel, et al., *Ann. Internal Med.*, 90, 85-91
25 (1979). An example of an HDL raising agent is nicotinic acid, but the quantities needed
to achieve HDL elevation are associated with undesirable effects, such as flushing.

There are several treatments currently available for treating diabetes
mellitus but these treatments still remain unsatisfactory and have limitations. While
physical exercise and reduction in dietary intake of calories will improve the diabetic
30 condition, compliance with this approach can be poor because of sedentary lifestyles and
excess food consumption, in particular high fat-containing food. Therefore, treatment
with hypoglycemics, such as sulfonylureas (e.g., chlorpropamide, tolbutamide,
tolazamide and acetohexamide) and biguanides (e.g. phenformin and metformin) are
often necessary as the disease progresses. Sulfonylureas stimulate the β cells of the
35 pancreas to secrete more insulin as the disease progresses. However, the response of the
 β cells eventually fails and treatment with insulin injections is necessary. In addition,

5 both sulfonylurea treatment and insulin injection have the life threatening side effect of hypoglycemic coma, and thus patients using these treatments must carefully control dosage.

10 It has been well established that improved glycemic control in patients with diabetes (Type I and Type II) is accompanied by decreased microvascular complications (DCCT and UKPDS). Due to difficulty in maintaining adequate glycemic control over time in patients with Type II diabetes, the use of insulin sensitizers in the therapy of Type II diabetes is growing. There is also a growing body of evidence that PPAR γ agonist, insulin sensitizer, may have benefits in the treatment of Type II diabetes beyond their effects in improving glycemic control.

15 In the last decade a class of compounds known as thiazolidinediones (e.g. U.S. Pat. Nos. 5,089,514; 4,342,771; 4,367,234; 4,340,605; and 5,306,726) have emerged as effective antidiabetic agents that have been shown to increase the sensitivity of insulin sensitive tissues, such as skeletal muscle, liver and adipose, to insulin. Increasing insulin sensitivity rather than the amount of insulin in the blood reduces the likelihood of
20 hypoglycemic coma. Although thiazolidinediones have been shown to increase insulin sensitivity by binding to PPAR γ receptors, this treatment also produces unwanted side effects such as weight gain and, for troglitazone, liver toxicity.

In view of the above, there exists a need for new pharmaceutical agents which modulate these receptors to prevent, treat and/or alleviate these diseases or
25 conditions while ameliorating side effects of current treatments.